Examination of High-Level Language Skills in 2 Phases of Multiple Sclerosis (Relapsing-Remitting & Secondary Progressive) in Comparison With Healthy Counterparts

多发性硬化症两阶段(复发缓解型和继发进展型)患者与健康对照组高级语言技能的比较研究

阅读:1

Abstract

BACKGROUND: Language skills compromised after neurological damage, such as multiple sclerosis (MS), significantly impacting patients' quality of life. MS impairs high-level language functioning. Despite existing research, no studies have examined high-level language functions during different phases of the disease. This is crucial for a better understanding of the linguistic profiles of affected patients. METHODS: This descriptive-analytical study included 25 patients with RRMS, 27 patients with SPMS, and 30 healthy individuals (age range, 22-57 years). They were selected based on convenience sampling. All participants were sampled using the Persian version of the high-level language skills assessment test. The Kruskal-Wallis test was used to compare the performance of the 3 groups, and the Bonferroni test was employed to make pairwise comparisons between groups. RESULTS: The Kruskal-Wallis test revealed significant differences in the total score and all subtest scores (P ≤ 0.05), except for the ambiguous sentence comprehension subtest (P ≥ 0.05). The Bonferroni test revealed a significant difference in the total score and all subtest scores (P ≤ 0.05) between healthy individuals and those with SPMS & RRMS, except for the ambiguous sentence comprehension subtest (P ≤ 0.05). Also, no significant differences were found in the total score and all subtest scores between the SPMS and RRMS patients (P ≥ 0.05). CONCLUSION: The results of the present study showed that the high-level language functions were weaker in MS patients compared to healthy individuals. However, no significant difference was found between the RRMS and SPMS patients.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。